FGFR2 and intrahepatic cholangiocarcinoma: In parallel, studies characterizing the mutational landscape of ICC have led to the development of drugs selectively targeting isocitrate dehydrogenase 1 (IDH1) and fibroblast growth receptor 2 (FGFR2) [14,15,16].